Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MP0274 · 1 trial · 1 indication
Number and grading according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE)
| Arm | Type | Description |
|---|---|---|
| MP0274 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| MP0274 | DRUG | Intravenous infusion of MP0274 as single agent at four planned dose levels, every three weeks until progressive disease, unacceptable toxicity or patient withdrawal for other reasons |
INCLUSION CRITERIA 1. Have signed and dated written informed consent prior to performing any study procedure, including screening 2. Are ≥ 18 years old on the day of signing informed consent 3. Have histologically confirmed and documented HER2 positive solid tumor malignancy that is unresectable, l...
Top 14 of 16 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Bristol-Myers Squibb Company | BMY | 5 | PHASE3 | Luspatercept, Fedratinib, BMS-986158 |
| AbbVie, Inc. | ABBV | 4 | PHASE3 | Navitoclax, ABBV-744, IMGN632 |
| Novartis AG Sponsored ADR | NVS | 3 | PHASE3 | Pelabresib, Ruxolitinib |
| Karyopharm Therapeutics, Inc. | KPTI | 4 | PHASE3 | Selinexor |
| Takeda Pharmaceutical Co. Ltd. Sponsored ADR | TAK | 2 | PHASE3 | Elritercept |
| Geron Corporation | GERN | 2 | PHASE3 | Imetelstat |
| Incyte Corporation | INCY | 8 | PHASE2 | Ruxolitinib, INCB160058, INCB057643, INCA033989, INCA036978 |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| GSK plc Sponsored ADR | GSK | 3 | PHASE2 | Momelotinib |
| Eli Lilly and Company | LLY | 2 | PHASE1 | LY3410738, LY5830966 |
| Disc Medicine, Inc. | IRON | 1 | PHASE1 | DISC-0974 |
| Damora Therapeutics, Inc. | DMRA | 2 | PHASE2 | GB2064, DMR-001 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Syndax Pharmaceuticals Inc | SNDX | 1 | PHASE1 | Revumenib |
MP0274 is an investigational small molecule developed by Molecular Partners AG for the treatment of neoplasms, specifically HER2-positive solid tumors. It has been studied in a single Phase 1 first-in-human clinical trial. It is not an approved therapy and remains in clinical development.
MP0274 was studied for the treatment of HER2-positive solid tumors, a subset of neoplasms. The Phase 1 trial enrolled cancer patients with HER2-positive solid tumors. As an investigational agent, MP0274 is not approved for any indication and is not available for routine clinical use.
MP0274 is developed by Molecular Partners AG, a biopharmaceutical company traded under the ticker MOLN. The company sponsored the first-in-human Phase 1 study of MP0274 in patients with HER2-positive solid tumors.
MP0274 is in Phase 1 development. One Phase 1 first-in-human trial has been completed, and no active trials are currently listed. The study enrolled 22 patients and evaluated safety, blood levels, and activity in cancer patients with HER2-positive solid tumors.
MP0274 has been evaluated in one clinical trial, NCT03084926, titled a first-in-human study to investigate safety, blood levels, and activity of MP0274 in cancer patients with HER2-positive solid tumors. The Phase 1 trial is completed and enrolled 22 patients across Germany, Switzerland, and the United Kingdom.
No. MP0274 is an investigational drug in Phase 1 clinical development and has not been approved by the FDA or any regulatory agency. Its only completed trial was a first-in-human Phase 1 study in patients with HER2-positive solid tumors.